Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2010 - 2026)

Jazz Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $11.9 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 2.82% year-over-year to $11.9 billion; the TTM figure through Mar 2026 stood at $45.8 billion (down 2.85% YoY), while the FY2025 annual figure was $11.7 billion, down 2.94% from the prior year.
• Liabilities and Shareholders Equity was $11.9 billion for Q1 2026 at Jazz Pharmaceuticals, up from $11.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.3 billion in Q3 2024 to a low of $10.4 billion in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $11.4 billion across 5 years, with a median of $11.4 billion in 2025.
• Biggest YoY gain for Liabilities and Shareholders Equity was 74.19% in 2022; the steepest drop was 16.78% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then advanced by 5.43% to $12.0 billion in 2024, then fell by 2.94% to $11.7 billion in 2025, then grew by 1.72% to $11.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $11.9 billion (Q1 2026), $11.7 billion (Q4 2025), and $11.4 billion (Q3 2025), per Business Quant data.